Compile Data Set for Download or QSAR
Report error Found 47 Enz. Inhib. hit(s) with all data for entry = 11448
TargetMuscarinic acetylcholine receptor M1(Human)
Pipeline Therapeutics

US Patent
LigandPNGBDBM616888(US11752149, Example 1)
Affinity DataIC50: 10nMAssay Description:Primary compound plates were prepared in 100% DMSO in opaque 96-well plates (VWR) and serially diluted in half log increments. Secondary compound pla...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/20/2023
Entry Details
Go to US Patent

TargetMuscarinic acetylcholine receptor M1(Human)
Pipeline Therapeutics

US Patent
LigandPNGBDBM616894(US11752149, Example 3)
Affinity DataIC50: 10nMAssay Description:Primary compound plates were prepared in 100% DMSO in opaque 96-well plates (VWR) and serially diluted in half log increments. Secondary compound pla...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/20/2023
Entry Details
Go to US Patent

TargetMuscarinic acetylcholine receptor M1(Human)
Pipeline Therapeutics

US Patent
LigandPNGBDBM616896(US11752149, Example 4)
Affinity DataIC50: 10nMAssay Description:Primary compound plates were prepared in 100% DMSO in opaque 96-well plates (VWR) and serially diluted in half log increments. Secondary compound pla...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/20/2023
Entry Details
Go to US Patent

TargetMuscarinic acetylcholine receptor M1(Human)
Pipeline Therapeutics

US Patent
LigandPNGBDBM616973(US11752149, Example 35 | US11752149, Example 36 | ...)
Affinity DataIC50: 10nMAssay Description:Primary compound plates were prepared in 100% DMSO in opaque 96-well plates (VWR) and serially diluted in half log increments. Secondary compound pla...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/20/2023
Entry Details
Go to US Patent

TargetMuscarinic acetylcholine receptor M1(Human)
Pipeline Therapeutics

US Patent
LigandPNGBDBM616928(6-{3-[3-(3-fluoro-2- methylbenzenesulfonyl) propan...)
Affinity DataIC50: 10nMAssay Description:Primary compound plates were prepared in 100% DMSO in opaque 96-well plates (VWR) and serially diluted in half log increments. Secondary compound pla...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/20/2023
Entry Details
Go to US Patent

TargetMuscarinic acetylcholine receptor M4(Human)
Pipeline Therapeutics

US Patent
LigandPNGBDBM616973(US11752149, Example 35 | US11752149, Example 36 | ...)
Affinity DataIC50: 55nMMore data for this Ligand-Target Pair
In Depth
Date in BDB:
10/20/2023
Entry Details
Go to US Patent

TargetMuscarinic acetylcholine receptor M2(Human)
Pipeline Therapeutics

US Patent
LigandPNGBDBM616973(US11752149, Example 35 | US11752149, Example 36 | ...)
Affinity DataIC50: 55nMMore data for this Ligand-Target Pair
In Depth
Date in BDB:
10/20/2023
Entry Details
Go to US Patent

TargetMuscarinic acetylcholine receptor M1(Human)
Pipeline Therapeutics

US Patent
LigandPNGBDBM616943(6-(3-{3-[(2-cyclopropylpyridin- 3-yl)sulfonyl]prop...)
Affinity DataIC50: 55nMAssay Description:Primary compound plates were prepared in 100% DMSO in opaque 96-well plates (VWR) and serially diluted in half log increments. Secondary compound pla...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/20/2023
Entry Details
Go to US Patent

TargetMuscarinic acetylcholine receptor M1(Human)
Pipeline Therapeutics

US Patent
LigandPNGBDBM616915(2-fluoro-4-{3-[3-(3- methoxybenzenesulfonyl) propa...)
Affinity DataIC50: 55nMAssay Description:Primary compound plates were prepared in 100% DMSO in opaque 96-well plates (VWR) and serially diluted in half log increments. Secondary compound pla...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/20/2023
Entry Details
Go to US Patent

TargetMuscarinic acetylcholine receptor M1(Human)
Pipeline Therapeutics

US Patent
LigandPNGBDBM616908(6-(3-{3-[(2-methoxypyridin-4- yl)sulfonyl]propanoy...)
Affinity DataIC50: 55nMAssay Description:Primary compound plates were prepared in 100% DMSO in opaque 96-well plates (VWR) and serially diluted in half log increments. Secondary compound pla...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/20/2023
Entry Details
Go to US Patent

TargetMuscarinic acetylcholine receptor M1(Human)
Pipeline Therapeutics

US Patent
LigandPNGBDBM616907(6-{3-[3-(3-fluoro-2- methoxybenzenesulfonyl) propa...)
Affinity DataIC50: 55nMAssay Description:Primary compound plates were prepared in 100% DMSO in opaque 96-well plates (VWR) and serially diluted in half log increments. Secondary compound pla...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/20/2023
Entry Details
Go to US Patent

TargetMuscarinic acetylcholine receptor M1(Human)
Pipeline Therapeutics

US Patent
LigandPNGBDBM616906(6-{3-[3-(5-fluoro-2- methoxybenzenesulfonyl) propa...)
Affinity DataIC50: 55nMAssay Description:Primary compound plates were prepared in 100% DMSO in opaque 96-well plates (VWR) and serially diluted in half log increments. Secondary compound pla...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/20/2023
Entry Details
Go to US Patent

TargetMuscarinic acetylcholine receptor M1(Human)
Pipeline Therapeutics

US Patent
LigandPNGBDBM616904(6-{3-[3-(3-fluoro-5- methoxybenzenesulfonyl) propa...)
Affinity DataIC50: 55nMAssay Description:Primary compound plates were prepared in 100% DMSO in opaque 96-well plates (VWR) and serially diluted in half log increments. Secondary compound pla...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/20/2023
Entry Details
Go to US Patent

TargetMuscarinic acetylcholine receptor M1(Human)
Pipeline Therapeutics

US Patent
LigandPNGBDBM616890(US11752149, Example 2)
Affinity DataIC50: 55nMAssay Description:Primary compound plates were prepared in 100% DMSO in opaque 96-well plates (VWR) and serially diluted in half log increments. Secondary compound pla...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/20/2023
Entry Details
Go to US Patent

TargetMuscarinic acetylcholine receptor M1(Human)
Pipeline Therapeutics

US Patent
LigandPNGBDBM616897(US11752149, Example 5)
Affinity DataIC50: 55nMAssay Description:Primary compound plates were prepared in 100% DMSO in opaque 96-well plates (VWR) and serially diluted in half log increments. Secondary compound pla...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/20/2023
Entry Details
Go to US Patent

TargetMuscarinic acetylcholine receptor M1(Human)
Pipeline Therapeutics

US Patent
LigandPNGBDBM616899(6-{3-[3-(3- fluorobenzenesulfonyl)propanoyl]- 3,8-...)
Affinity DataIC50: 55nMAssay Description:Primary compound plates were prepared in 100% DMSO in opaque 96-well plates (VWR) and serially diluted in half log increments. Secondary compound pla...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/20/2023
Entry Details
Go to US Patent

TargetMuscarinic acetylcholine receptor M1(Human)
Pipeline Therapeutics

US Patent
LigandPNGBDBM616900(6-{3-[3-(3,5- difluorobenzenesulfonyl) propanoyl]-...)
Affinity DataIC50: 55nMAssay Description:Primary compound plates were prepared in 100% DMSO in opaque 96-well plates (VWR) and serially diluted in half log increments. Secondary compound pla...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/20/2023
Entry Details
Go to US Patent

TargetMuscarinic acetylcholine receptor M1(Human)
Pipeline Therapeutics

US Patent
LigandPNGBDBM616905(6-{3-[3-(2- methoxybenzenesulfonyl) propanoyl]-3,8...)
Affinity DataIC50: 55nMAssay Description:Primary compound plates were prepared in 100% DMSO in opaque 96-well plates (VWR) and serially diluted in half log increments. Secondary compound pla...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/20/2023
Entry Details
Go to US Patent

TargetMuscarinic acetylcholine receptor M1(Human)
Pipeline Therapeutics

US Patent
LigandPNGBDBM616972(6-(3-(3-((3-fluoro-5- methylphenyl)sulfonyl) propa...)
Affinity DataIC50: 550nMAssay Description:Primary compound plates were prepared in 100% DMSO in opaque 96-well plates (VWR) and serially diluted in half log increments. Secondary compound pla...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/20/2023
Entry Details
Go to US Patent

TargetMuscarinic acetylcholine receptor M3(Human)
Pipeline Therapeutics

US Patent
LigandPNGBDBM616973(US11752149, Example 35 | US11752149, Example 36 | ...)
Affinity DataIC50: 550nMMore data for this Ligand-Target Pair
In Depth
Date in BDB:
10/20/2023
Entry Details
Go to US Patent

TargetMuscarinic acetylcholine receptor M4(Human)
Pipeline Therapeutics

US Patent
LigandPNGBDBM616928(6-{3-[3-(3-fluoro-2- methylbenzenesulfonyl) propan...)
Affinity DataIC50: 550nMMore data for this Ligand-Target Pair
In Depth
Date in BDB:
10/20/2023
Entry Details
Go to US Patent

TargetMuscarinic acetylcholine receptor M3(Human)
Pipeline Therapeutics

US Patent
LigandPNGBDBM616928(6-{3-[3-(3-fluoro-2- methylbenzenesulfonyl) propan...)
Affinity DataIC50: 550nMMore data for this Ligand-Target Pair
In Depth
Date in BDB:
10/20/2023
Entry Details
Go to US Patent

TargetMuscarinic acetylcholine receptor M4(Human)
Pipeline Therapeutics

US Patent
LigandPNGBDBM616894(US11752149, Example 3)
Affinity DataIC50: 550nMMore data for this Ligand-Target Pair
In Depth
Date in BDB:
10/20/2023
Entry Details
Go to US Patent

TargetMuscarinic acetylcholine receptor M3(Human)
Pipeline Therapeutics

US Patent
LigandPNGBDBM616894(US11752149, Example 3)
Affinity DataIC50: 550nMMore data for this Ligand-Target Pair
In Depth
Date in BDB:
10/20/2023
Entry Details
Go to US Patent

TargetMuscarinic acetylcholine receptor M4(Human)
Pipeline Therapeutics

US Patent
LigandPNGBDBM616890(US11752149, Example 2)
Affinity DataIC50: 550nMMore data for this Ligand-Target Pair
In Depth
Date in BDB:
10/20/2023
Entry Details
Go to US Patent

TargetMuscarinic acetylcholine receptor M3(Human)
Pipeline Therapeutics

US Patent
LigandPNGBDBM616890(US11752149, Example 2)
Affinity DataIC50: 550nMMore data for this Ligand-Target Pair
In Depth
Date in BDB:
10/20/2023
Entry Details
Go to US Patent

TargetMuscarinic acetylcholine receptor M1(Human)
Pipeline Therapeutics

US Patent
LigandPNGBDBM616973(US11752149, Example 35 | US11752149, Example 36 | ...)
Affinity DataIC50: 550nMAssay Description:Primary compound plates were prepared in 100% DMSO in opaque 96-well plates (VWR) and serially diluted in half log increments. Secondary compound pla...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/20/2023
Entry Details
Go to US Patent

TargetMuscarinic acetylcholine receptor M1(Human)
Pipeline Therapeutics

US Patent
LigandPNGBDBM616971(6-(3-(3-((5-fluoro-2- methylphenyl)sulfonyl) propa...)
Affinity DataIC50: 550nMAssay Description:Primary compound plates were prepared in 100% DMSO in opaque 96-well plates (VWR) and serially diluted in half log increments. Secondary compound pla...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/20/2023
Entry Details
Go to US Patent

TargetMuscarinic acetylcholine receptor M1(Human)
Pipeline Therapeutics

US Patent
LigandPNGBDBM616970(6-(3-(3-((2-(1,1- difluoroethyl)phenyl)sulfonyl) p...)
Affinity DataIC50: 550nMAssay Description:Primary compound plates were prepared in 100% DMSO in opaque 96-well plates (VWR) and serially diluted in half log increments. Secondary compound pla...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/20/2023
Entry Details
Go to US Patent

TargetMuscarinic acetylcholine receptor M1(Human)
Pipeline Therapeutics

US Patent
LigandPNGBDBM616968(6-(3-(3-((2- (trifluoromethyl)phenyl)sulfonyl) pro...)
Affinity DataIC50: 550nMAssay Description:Primary compound plates were prepared in 100% DMSO in opaque 96-well plates (VWR) and serially diluted in half log increments. Secondary compound pla...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/20/2023
Entry Details
Go to US Patent

TargetMuscarinic acetylcholine receptor M1(Human)
Pipeline Therapeutics

US Patent
LigandPNGBDBM616913(2-fluoro-5-{3-[3-(3- methoxybenzenesulfonyl) propa...)
Affinity DataIC50: 550nMAssay Description:Primary compound plates were prepared in 100% DMSO in opaque 96-well plates (VWR) and serially diluted in half log increments. Secondary compound pla...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/20/2023
Entry Details
Go to US Patent

TargetMuscarinic acetylcholine receptor M1(Human)
Pipeline Therapeutics

US Patent
LigandPNGBDBM616901(3-(3-methoxybenzenesulfonyl)-1- [8-(6-methylpyrida...)
Affinity DataIC50: 550nMAssay Description:Primary compound plates were prepared in 100% DMSO in opaque 96-well plates (VWR) and serially diluted in half log increments. Secondary compound pla...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/20/2023
Entry Details
Go to US Patent

TargetMuscarinic acetylcholine receptor M1(Human)
Pipeline Therapeutics

US Patent
LigandPNGBDBM616917(6-{3-[3-(3- cyclopropoxybenzenesulfonyl) propanoyl...)
Affinity DataIC50: 550nMAssay Description:Primary compound plates were prepared in 100% DMSO in opaque 96-well plates (VWR) and serially diluted in half log increments. Secondary compound pla...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/20/2023
Entry Details
Go to US Patent

TargetMuscarinic acetylcholine receptor M1(Human)
Pipeline Therapeutics

US Patent
LigandPNGBDBM616923(6-{3-[3-(3- bromobenzenesulfonyl) propanoyl]-3,8-d...)
Affinity DataIC50: 550nMAssay Description:Primary compound plates were prepared in 100% DMSO in opaque 96-well plates (VWR) and serially diluted in half log increments. Secondary compound pla...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/20/2023
Entry Details
Go to US Patent

TargetMuscarinic acetylcholine receptor M1(Human)
Pipeline Therapeutics

US Patent
LigandPNGBDBM616926(6-(3-{3-[(3-cyclopropylpyridin- 2-yl)sulfonyl]prop...)
Affinity DataIC50: 550nMAssay Description:Primary compound plates were prepared in 100% DMSO in opaque 96-well plates (VWR) and serially diluted in half log increments. Secondary compound pla...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/20/2023
Entry Details
Go to US Patent

TargetMuscarinic acetylcholine receptor M1(Human)
Pipeline Therapeutics

US Patent
LigandPNGBDBM616911(3-(3-methoxybenzenesulfonyl)-1- {8-[6-(trifluorome...)
Affinity DataIC50: 550nMAssay Description:Primary compound plates were prepared in 100% DMSO in opaque 96-well plates (VWR) and serially diluted in half log increments. Secondary compound pla...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/20/2023
Entry Details
Go to US Patent

TargetMuscarinic acetylcholine receptor M1(Human)
Pipeline Therapeutics

US Patent
LigandPNGBDBM616933(6-(3-{3-[(2-cyclopropyl- pyridin-4-yl)sulfonyl] pr...)
Affinity DataIC50: 550nMAssay Description:Primary compound plates were prepared in 100% DMSO in opaque 96-well plates (VWR) and serially diluted in half log increments. Secondary compound pla...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/20/2023
Entry Details
Go to US Patent

TargetMuscarinic acetylcholine receptor M1(Human)
Pipeline Therapeutics

US Patent
LigandPNGBDBM616941(6-(3-{3-[2- (difluoromethyl)benzene- sulfonyl]prop...)
Affinity DataIC50: 550nMAssay Description:Primary compound plates were prepared in 100% DMSO in opaque 96-well plates (VWR) and serially diluted in half log increments. Secondary compound pla...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/20/2023
Entry Details
Go to US Patent

TargetMuscarinic acetylcholine receptor M1(Human)
Pipeline Therapeutics

US Patent
LigandPNGBDBM616909(3-(3-methoxybenzenesulfonyl)-1- {8-[5-(trifluorome...)
Affinity DataIC50: 550nMAssay Description:Primary compound plates were prepared in 100% DMSO in opaque 96-well plates (VWR) and serially diluted in half log increments. Secondary compound pla...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/20/2023
Entry Details
Go to US Patent

TargetMuscarinic acetylcholine receptor M1(Human)
Pipeline Therapeutics

US Patent
LigandPNGBDBM616950(6-(3-(3-((2- bromophenyl)sulfonyl) propanoyl)-3,8-...)
Affinity DataIC50: 550nMAssay Description:Primary compound plates were prepared in 100% DMSO in opaque 96-well plates (VWR) and serially diluted in half log increments. Secondary compound pla...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/20/2023
Entry Details
Go to US Patent

TargetMuscarinic acetylcholine receptor M1(Human)
Pipeline Therapeutics

US Patent
LigandPNGBDBM616969(6-(3-(3-((2- (trifluoromethoxy)phenyl) sulfonyl)pr...)
Affinity DataIC50: 550nMAssay Description:Primary compound plates were prepared in 100% DMSO in opaque 96-well plates (VWR) and serially diluted in half log increments. Secondary compound pla...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/20/2023
Entry Details
Go to US Patent

TargetMuscarinic acetylcholine receptor M2(Human)
Pipeline Therapeutics

US Patent
LigandPNGBDBM616928(6-{3-[3-(3-fluoro-2- methylbenzenesulfonyl) propan...)
Affinity DataIC50: 5.50E+3nMMore data for this Ligand-Target Pair
In Depth
Date in BDB:
10/20/2023
Entry Details
Go to US Patent

TargetMuscarinic acetylcholine receptor M1(Human)
Pipeline Therapeutics

US Patent
LigandPNGBDBM616898(US11752149, Example 6)
Affinity DataIC50: 5.50E+3nMAssay Description:Primary compound plates were prepared in 100% DMSO in opaque 96-well plates (VWR) and serially diluted in half log increments. Secondary compound pla...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/20/2023
Entry Details
Go to US Patent

TargetMuscarinic acetylcholine receptor M1(Human)
Pipeline Therapeutics

US Patent
LigandPNGBDBM616912(3-(3-methoxybenzenesulfonyl)- 1-[8-(5-methylpyridi...)
Affinity DataIC50: 5.50E+3nMAssay Description:Primary compound plates were prepared in 100% DMSO in opaque 96-well plates (VWR) and serially diluted in half log increments. Secondary compound pla...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/20/2023
Entry Details
Go to US Patent

TargetMuscarinic acetylcholine receptor M1(Human)
Pipeline Therapeutics

US Patent
LigandPNGBDBM616902(3-(3-methoxybenzenesulfonyl)-1- [8-(6-methylpyridi...)
Affinity DataIC50: 5.50E+3nMAssay Description:Primary compound plates were prepared in 100% DMSO in opaque 96-well plates (VWR) and serially diluted in half log increments. Secondary compound pla...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/20/2023
Entry Details
Go to US Patent

TargetMuscarinic acetylcholine receptor M2(Human)
Pipeline Therapeutics

US Patent
LigandPNGBDBM616894(US11752149, Example 3)
Affinity DataIC50: 1.00E+4nMMore data for this Ligand-Target Pair
In Depth
Date in BDB:
10/20/2023
Entry Details
Go to US Patent

TargetMuscarinic acetylcholine receptor M2(Human)
Pipeline Therapeutics

US Patent
LigandPNGBDBM616890(US11752149, Example 2)
Affinity DataIC50: 1.00E+4nMMore data for this Ligand-Target Pair
In Depth
Date in BDB:
10/20/2023
Entry Details
Go to US Patent